Profile data is unavailable for this security.
About the company
Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic process and finished formulations. The Company’s offerings span both bio-pharmaceutical APIs and formulations across therapeutic areas like immunosuppressants oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in anti-bacterial, anti-fungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, Teicoplanin, Polymyxin B Sulfate, Fidaxomicin, Anidulafungin. Its API products under development include Daptomycin, Epirubicin, Idarubicin, and Pirarubicin.
- Revenue in INR (TTM)10.38bn
- Net income in INR3.13bn
- Incorporated1984
- Employees1.38k
- LocationConcord Biotech Ltd10th FloorNr. Prahladnagar Garden, 100ft RoadAHMEDABAD 380015IndiaIND
- Phone+91 7 968138700
- Fax+91 2 714222504
- Websitehttp://www.concordbiotech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glenmark Life Sciences Ltd | 22.05bn | 4.24bn | 129.54bn | 2.01k | 30.67 | 5.10 | 26.95 | 5.88 | 34.47 | 34.47 | 179.44 | 207.17 | 0.7304 | 1.46 | 2.79 | 10,947,850.00 | 14.03 | 18.28 | 16.69 | 29.99 | 54.92 | 53.40 | 19.21 | 20.23 | 3.03 | 380.55 | 0.0063 | 26.37 | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
Marksans Pharma Ltd | 22.68bn | 3.34bn | 131.26bn | 2.00k | 39.29 | -- | 31.66 | 5.79 | 7.37 | 7.37 | 50.09 | -- | -- | -- | -- | 11,339,960.00 | -- | 14.62 | -- | 18.52 | 53.39 | 50.52 | 14.71 | 14.03 | -- | 32.19 | -- | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
Akums Drugs and Pharmaceuticals Ltd | -100.00bn | -100.00bn | 132.51bn | 7.39k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.32 | -- | -104.25 | -- | -- | -- |
Granules India Ltd | 47.01bn | 4.92bn | 138.05bn | 4.12k | 28.07 | -- | 19.64 | 2.94 | 20.29 | 20.29 | 193.87 | -- | -- | -- | -- | 11,403,970.00 | -- | 10.68 | -- | 16.18 | 56.89 | 48.83 | 10.47 | 11.82 | -- | 6.95 | -- | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
Strides Pharma Science Ltd | 44.10bn | 1.77bn | 143.04bn | 3.07k | 80.93 | 6.29 | 38.48 | 3.24 | 19.22 | 25.15 | 479.84 | 247.16 | 0.7155 | 1.50 | 3.57 | 14,389,290.00 | 2.79 | -1.68 | 5.43 | -2.97 | 60.19 | 51.39 | 3.91 | -3.36 | 0.6355 | 1.52 | 0.5103 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
Caplin Point Laboratories Ltd | 17.58bn | 4.78bn | 154.71bn | 859.00 | 32.48 | -- | 28.64 | 8.80 | 62.67 | 62.67 | 230.62 | -- | -- | -- | -- | 20,462,630.00 | -- | 19.83 | -- | 22.82 | 58.41 | 53.38 | 27.43 | 25.39 | -- | 1,525.59 | -- | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
Sanofi India Ltd | 23.83bn | 4.30bn | 156.48bn | 2.17k | 36.41 | 22.86 | 33.44 | 6.57 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
Eris Lifesciences Ltd | 24.98bn | 3.48bn | 180.09bn | 3.08k | 51.74 | 6.49 | 28.91 | 7.21 | 25.57 | 25.57 | 183.35 | 203.74 | 0.4585 | 2.90 | 5.96 | 8,110,753.00 | 6.73 | 13.42 | 8.39 | 16.80 | 77.03 | 79.98 | 14.69 | 24.96 | 0.8599 | 3.41 | 0.4626 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
Wockhardt Ltd | 28.93bn | -3.43bn | 185.39bn | 2.39k | -- | -- | -- | 6.41 | -23.75 | -23.75 | 199.60 | -- | -- | -- | -- | 12,084,380.00 | -- | -4.56 | -- | -8.29 | 58.66 | 55.26 | -12.17 | -12.70 | -- | 0.0764 | -- | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 187.40bn | 1.65k | 55.76 | -- | 47.03 | 11.46 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 190.62bn | 940.00 | 198.86 | -- | 171.87 | 13.74 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
Concord Biotech Ltd | 10.38bn | 3.13bn | 191.48bn | 1.38k | 61.15 | -- | 52.18 | 18.45 | 29.93 | 29.93 | 99.19 | -- | -- | -- | -- | 7,537,496.00 | -- | -- | -- | -- | 77.16 | -- | 30.18 | -- | -- | 115.93 | -- | -- | 19.20 | -- | 28.33 | -- | -- | -- |
Jubilant Pharmova Ltd | 69.20bn | 5.93bn | 191.94bn | 995.00 | 32.41 | 3.23 | 19.86 | 2.77 | 37.38 | 37.38 | 436.41 | 375.04 | 0.5934 | 1.75 | 8.15 | 69,544,720.00 | 5.05 | 2.96 | 6.01 | 3.55 | 68.50 | 68.47 | 8.51 | 5.13 | 1.20 | 2.51 | 0.342 | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
Alembic Pharmaceuticals Ltd | 63.04bn | 6.30bn | 221.89bn | 14.86k | 35.23 | -- | 24.51 | 3.52 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
Pfizer Ltd | 22.38bn | 6.18bn | 233.22bn | 1.72k | 37.75 | 6.22 | 34.36 | 10.42 | 135.06 | 135.06 | 489.19 | 819.90 | 0.5288 | 1.83 | 11.16 | 13,004,360.00 | 14.60 | 14.22 | 17.05 | 17.71 | 65.00 | 61.37 | 27.61 | 24.05 | 4.30 | 46.21 | 0.0267 | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
Natco Pharma Ltd. | 42.21bn | 16.37bn | 251.28bn | 4.02k | 15.35 | -- | 13.78 | 5.95 | 91.37 | 91.37 | 235.68 | -- | -- | -- | -- | 10,510,210.00 | -- | 12.33 | -- | 14.25 | 83.40 | 73.05 | 38.77 | 25.16 | -- | 91.13 | -- | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -4.71 | 14.87 |
Holder | Shares | % Held |
---|---|---|
Norges Bank Investment Managementas of 31 Mar 2024 | 2.26m | 2.16% |
The Vanguard Group, Inc.as of 02 Oct 2024 | 1.75m | 1.67% |
Max Life Insurance Co. Ltd.as of 31 Mar 2024 | 1.59m | 1.52% |
HSBC Global Asset Management (Hong Kong) Ltd.as of 31 Aug 2024 | 1.21m | 1.16% |
Invesco Asset Management (India) Pvt Ltd.as of 30 Sep 2024 | 1.09m | 1.04% |
HSBC Asset Management (India) Pvt Ltd.as of 30 Sep 2024 | 1.07m | 1.02% |
Tata AIA Life Insurance Co. Ltd.as of 30 Sep 2024 | 1.06m | 1.01% |
Edelweiss Asset Management Ltd.as of 30 Sep 2024 | 788.89k | 0.75% |
Baroda BNP Paribas Asset Management India Pvt Ltd.as of 15 Oct 2024 | 647.72k | 0.62% |
DSP Asset Managers Pvt. Ltd.as of 30 Sep 2024 | 583.97k | 0.56% |